CHAPAS-3 trial supports WHO’s recommendation on how to treat children with HIV

18 Nov 2015

The results of the CHAPAS-3 trial have recently been published in the Lancet Journal of Infectious Diseases. The trial, which took place in Uganda and Zambia, investigated the safety and effectiveness of three different drugs when used as part of a combination to treat HIV-infected children.

The current World Health Organisation guidelines for treatment of both adults and children recommend a combination of two NRTI drugs, together with a drug from another class. In CHAPAS-3, children were randomly allocated to one of three groups, to receive either:

  • Abacavir + lamivudine + a drug from another class (NNRTI)
  • Zidovudine + lamivudine + a drug from another class (NNRTI)
  • Stavudine + lamivudine + a drug from another class (NNRTI)

An NRTI drug works by blocking the enzyme called reverse transcriptase which the HIV virus uses to make copies of itself when it enters a healthy cell. Without reverse transcriptase, HIV cannot make new virus copies of itself, so cannot spread.

No trials had previously compared the effects of NRTIs in first-line antiretroviral therapy (ART) in children in Africa.

478 children took part in the trial; three quarters of them starting HIV treatment for the first time. The average age of those starting HIV treatment was around three years, though the average age of those who were already being treated for HIV was nearly seven. The children were followed up for around two years.

Most of the children in the CHAPAS-3 trial did very well. Only 6% had to change any of their initial drugs through the course of the study due to side-effects. 1% had to change to a completely new combination due to the drugs no longer working. Less than 4% of children in the study died, all of whom were starting HIV treatment for the first time.

The trial found no major differences between the NRTIs in terms of side effects, and how well children did. However, taking abacavir as the first course of treatment was shown to increase how well children later responded to a second course of treatment. Abacavir also has the advantage that it can be taken once daily, rather than twice, as part of a fixed dose combination tablet. This makes taking treatment easier for children and their carers.

Overall, this trial endorsed the WHO’s 2013 recommendation that abacavir is the preferred first NRTI for children; something which is expected to be reiterated in the World Health Organisation's forthcoming  2015 HIV treatment guidelines.


Further information: